HIV prevention-antibodies and vaccine development (part 1)
Lynn Morris began her talk comparing the HIV and SARS-Cov-2 epidemics, at the peak of the HIV epidemic approximately annual mortality was 1.8 million deaths reported due to HIV/AIDS.
HIV prevention-antibodies and vaccine development (part 2)
Prof Lynn Morris discussed results from the antibody-mediated prevention trial that tested the ability of VRC01 broadly neutralising antibody that binds the HIV envelope protein CD4 binding site, has a wide coverage of HIV subtype B and C strains in vitro studies. Participants in the AMP trials received 10 administrations of VRC01…
Immunopathology of COVID-19 lessons from pregnancy and ageing
Prof Cossarizza webinar focused on “Immunopathology of COVID-19 lessons from pregnancy and ageing.” Professor Cossarizza began his talk by highlighting the major role inflammation (and hyper inflammation) play in COVID-19…
Clinical representation of hyperinflammation
Fabrizio De Benedetti gave examples of clinical presentations and laboratory features of hyper-inflammation with a focus on hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).
In-depth characterisation of immune cells in Ebola virus
Anita McElroy describes the cellular immune landscape that occurs following Ebola virus infection and will correlate these findings with key features of Ebola virus disease.
Getting to the “bottom” of arthritis
In a recent IUIS-Immunopaedia-Frontiers in Immunology webinar, Claudia Mauri discussed how microbial products induce B-regs and their relevance for arthritis pathology. Murine models of arthritis have…
Immunology taught by Plasmodium falciparum
Using a systematic search for antibodies that bind broadly to infected erythrocytes, they discovered a new class of Abs generated by insertions of genomic DNA encoding human inhibitory receptors (LAIR1) into antibody genes…
The path to sterilizing immunity against tuberculosis 1
Dr Flynn began her talk with a brief overview of how M.tb infection can lead to the development of granulomas (structured organisation of cells that aim to contain M.tb replication). The majority of Dr Flynn research utilises non-human primate (NHPs) models, specifically cynomolgus (latent to active TB) and rhesus (almost always active TB) macaques, that represent the full spectrum of human TB infection and disease.
The path to sterilizing immunity against tuberculosis 2
Darrah et al., showed that BCG-IV resulted in superior T cell and antigen-presenting cell recruitment to the lung compared to other vaccination strategies. In addition to T cell and innate immunity, BCG-IV also induced superior…
Harnessing innate immunity from cancer therapy to COVID-19
In this webinar, Eric Vivier describes novel immunotherapies that aim to improve cancer and COVID-19 pathogenesis by targetting promoting NK cell-mediated and blocking C5a mediated immunity, respectively.
Immunoregulation and the tumor microenvironment
The first webinar of the year featured a talk by Pamela Ohashi
